The cleanest GH secretagogue.

Ipamorelin is a pentapeptide ghrelin mimetic with a selectivity profile no other GH secretagogue matches. It stimulates GH release without meaningful cortisol, prolactin, or ACTH co-secretion. Understanding why that selectivity matters changes how you use it.

I. Mechanism of action.

Ipamorelin is a synthetic pentapeptide ghrelin receptor agonist (GHS-R1a). Novo Nordisk developed it in the 1990s, and it was characterized in the late 1990s as one of the first highly selective growth hormone secretagogues. It binds GHS-R1a in the pituitary and hypothalamus, stimulating GH release directly and also stimulating increased hypothalamic GHRH (growth hormone-releasing hormone) output. verified [I]

The landmark characterization: Raun et al. (1998) demonstrated that at effective GH-stimulating doses, ipamorelin produced no significant changes in cortisol, prolactin, or ACTH. This distinguished it sharply from GHRP-2 and GHRP-6, which stimulate GH release but carry significant co-secretion of cortisol and prolactin at therapeutic doses. verified [I]

This selectivity is not a minor pharmacological footnote. It is the primary reason ipamorelin is the preferred GH secretagogue in clinical optimization use.

II. The selectivity advantage.

Comparing the major GH secretagogues on the axis that matters most, receptor selectivity at therapeutic dose:

GHRP-2 and GHRP-6: effective at stimulating GH but produce significant co-secretion of cortisol and prolactin at therapeutic doses. Cortisol co-secretion directly counteracts the anabolic GH response. The GH pulse is partially offset by the cortisol pulse it arrives with.

Ipamorelin: clean GH stimulation without meaningful HPA axis activation. The patient receives the GH pulse without the cortisol pulse that would blunt its anabolic effect. verified [I]

Hexarelin: potent GH secretagogue but produces the most significant cortisol and prolactin co-secretion in the class. It also downregulates GHS-R1a with chronic use faster than ipamorelin does. Neither property is favorable for long-term optimization protocols. verified [V]

III. The CJC-1295 pairing rationale.

CJC-1295 is a GHRH analog: it stimulates the GHRH receptor. Ipamorelin is a ghrelin mimetic: it stimulates GHS-R1a. These are two distinct receptor systems that converge on GH release through different intracellular pathways. That distinction is the pharmacodynamic basis for combining them.

GHRH receptor stimulation (CJC-1295) increases pituitary GH synthesis and sensitizes the pituitary to subsequent GHS-R1a stimulation. Ipamorelin then triggers the amplified release. The combined pulse amplitude is substantially higher than either compound alone. verified [V]

The two formulations of CJC-1295 have meaningfully different pharmacokinetic profiles and should not be treated as interchangeable:

CJC-1295 with DAC (drug affinity complex): the DAC modification binds albumin in circulation, extending the half-life to approximately 7 to 10 days. This creates a sustained GHRH-like background signal, producing more sustained IGF-1 elevation but blunting pulsatility. Weekly or twice-weekly injection.

CJC-1295 without DAC (Mod GRF 1-29): half-life of approximately 30 minutes. Injected simultaneously with ipamorelin for a synchronized GHRH-GHS pulse. More physiological pulsatility. The preferred combination for bedtime GH secretagogue protocols. verified [V]

IV. When ipamorelin alone is preferred.

The combination protocol is the standard for most optimization objectives, but four clinical situations favor ipamorelin as a solo agent:

Elevated baseline cortisol or HPA dysregulation. Ipamorelin without a GHRH analog avoids the larger combined GH pulse and the larger combined IGF-1 signal. A smaller, cleaner GH stimulus is appropriate until the cortisol axis is addressed. Adding CJC-1295 to a cortisol-dysregulated patient amplifies a system that is already dysregulated.

Personal or family history of cancer. The GHRH analog component, particularly CJC-1295 with DAC, produces a more sustained IGF-1 elevation. Some oncologists are uncomfortable with sustained IGF-1 elevation in patients with cancer history or strong family history. Ipamorelin alone produces a more transient IGF-1 signal with faster clearance. This is a risk-stratification decision, not a contraindication category. inferred from clinical pharmacology

Protocol initiation and response characterization. Starting a patient on ipamorelin 200 mcg alone for 4 to 6 weeks establishes a baseline GH response before the GHRH component is added. It allows the clinician to observe tolerability and IGF-1 response from a single variable. Combination protocols are harder to troubleshoot when the patient is new.

Cost-constrained protocols. Ipamorelin alone at 200 to 300 mcg before bed produces a clinically meaningful GH pulse at lower cost than the combination. For patients where budget is a limiting factor, ipamorelin alone is the correct starting point rather than no protocol at all.

V. Dosing protocol.

Standard combination: CJC-1295 without DAC 200 to 300 mcg plus ipamorelin 200 to 300 mcg, subcutaneous injection, 30 to 60 minutes before bed on an empty stomach. Minimum 3-hour fast before injection. Injected simultaneously in the same or separate syringes.

Ipamorelin alone: 200 to 300 mcg subcutaneous, same timing and fasting requirement.

Secondary daytime dose (twice-daily protocol): same dosing, 4 to 6 hours after the last meal in the afternoon. Cortisol and insulin must be at low points for a clean GH pulse. This timing is the most common compliance failure in twice-daily protocols.

Frequency: 5 days on, 2 days off is a common cycling pattern to limit GHS-R1a desensitization. Daily administration is also used in practice. No strong controlled trial data differentiates long-term outcome between the two patterns. inferred from clinical practice

VI. Monitoring and expected response.

IGF-1 at baseline, then at 3 months. Target: upper quartile of the age-adjusted reference range. IGF-1 is the practical surrogate for cumulative GH secretagogue effect in outpatient protocols. verified [V]

If IGF-1 fails to rise: evaluate injection technique, timing compliance, storage conditions, and vial integrity before adjusting dose. The most common cause of no IGF-1 response is injection timing failure or improper storage, not pharmacological non-response.

If IGF-1 rises above 300 ng/mL: reduce dose. Supraphysiological IGF-1 is not the objective.

Expected subjective improvements: improved sleep quality (slow-wave sleep depth), faster recovery from training, progressive improvement in body composition over 3 to 6 months, and possible improvement in skin quality. GH drives dermal collagen production via IGF-1 upregulation of fibroblast activity. verified [III]

Expected timeline: body composition changes become visible at 3 to 4 months with consistent protocol adherence. Subjective improvements in sleep quality and training recovery often present within 2 to 4 weeks. Patients who expect visible body composition changes in the first month will be disappointed. Setting this expectation before the protocol begins prevents premature discontinuation.

THE PIVOTAL PROTOCOL is an intelligence and education layer, not a prescriber. The mechanisms described here are derived from the cited literature and from Pivotal's own protocol design history. Every clinical decision belongs to a licensed physician with full knowledge of the case. Begin a conversation. Do not begin self-administration from a website.